Key result
Telcagepant competitively antagonizes CGRP-induced endothelium-independent vasodilation in human subcutaneous arteries.
Why the study?
The mechanism of CGRP-induced vasodilation varies by species and vessel type, and the localization and characteristics of CGRP receptors in human subcutaneous arteries are not fully understood.
CGRP induces endothelium-independent vasodilation in human subcutaneous arteries via smooth muscle cell receptors, which can be competitively antagonized by telcagepant.
CGRP antagonism may modulate human vascular tone ex vivo; leaves open in vivo hemodynamic effects and clinical translation.
AIM: Calcitonin gene-related peptide (CGRP) and its receptor are widely distributed within the circulation and the mechanism behind its vasodilation not only differs from one animal species to another but is also dependent on the type and size of vessel. The present study examines the nature of CGRP-induced vasodilation, characteristics of the CGRP receptor antagonist telcagepant and localization of the key components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) of the CGRP receptor in human subcutaneous arteries. METHODS: CGRP-induced vasodilation and receptor localization in human subcutaneous arteries were studied by wire myograph in the presence and absence of the CGRP receptor antagonist telcagepant and immunohistochemistry respectively. RESULTS: At concentrations of 1, 3, 5, 10 and 30 nm, telcagepant had a competitive antagonist-like behaviour characterized by a parallel rightwards shift in the log CGRP concentration-tension/calcium curve with no depression of the maximal relaxation. CGRP-induced vasodilation was not affected by mechanical removal of the endothelium or addition of L-NG-nitroarginine methyl ester and indomethacin, antagonists for synthesis of nitric oxide and prostaglandins, respectively. CLR and RAMP1 were localized in the vascular smooth muscle and endothelial cells. CONCLUSION: The present results indicate that CGRP exerts its vasodilatory effect in human subcutaneous arteries by binding to its receptors located on the smooth muscle cells and is suggested to be endothelium-independent. In conclusion, these results underline the dynamic distribution of CGRP receptor components in the human circulation reflecting the important role of CGRP in fine tuning of the blood flow in resistance arteries.
No takes yet. Share an insight, caveat, or question.
Edvinsson et al. (2013) studied this question. Telcagepant vs. Absence of telcagepant was evaluated on CGRP-induced vasodilation and receptor localization. Telcagepant competitively antagonized CGRP-induced endothelium-independent vasodilation in human subcutaneous arteries, with CGRP receptors localized on smooth muscle and endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: